玻璃体内注射贝伐单抗治疗特发性脉络膜新生血管化。

Intravitreal bevacizumab for idiopathic choroidal neovascularization.

作者信息

Cakir Mehmet, Cekiç Osman, Yilmaz O Faruk

机构信息

Beyoğlu Eye Training and Research Hospital, Istanbul, Turkey.

出版信息

J AAPOS. 2009 Jun;13(3):296-8. doi: 10.1016/j.jaapos.2008.12.003. Epub 2009 Mar 14.

DOI:10.1016/j.jaapos.2008.12.003

PMID:19285890

Abstract

An otherwise healthy 8-year-old girl with active juxtapapillary choroidal neovascularization was successfully treated with two intravitreal injections of bevacizumab. Intravitreal bevacizumab was well tolerated, choroidal neovascularization involuted, and subretinal and intraretinal serous fluid resorbed, with improvement in visual acuity from 20/400 to 20/50. The girl has remained stable for 6 months after the injections.

摘要

一名原本健康的8岁女孩患有活动性视乳头旁脉络膜新生血管，经两次玻璃体内注射贝伐单抗成功治疗。玻璃体内注射贝伐单抗耐受性良好，脉络膜新生血管消退，视网膜下和视网膜内浆液性积液吸收，视力从20/400提高到20/50。注射后该女孩已保持稳定6个月。